The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Utilizing circulating tumor DNA methylation levels to predict pathological and radiological response in hepatocellular carcinoma patients undergoing neoadjuvant and systemic therapy.
 
Shi-Yu Zhang
No Relationships to Disclose
 
De-Zhen Guo
No Relationships to Disclose
 
Min-Jie Xu
Employment - Singlera?Genomics?(Shanghai)?Ltd
 
Rui-Qing Fu
Employment - Singlera?Genomics?(Shanghai)?Ltd
 
Ming-Yang Su
Employment - Singlera?Genomics?(Shanghai)?Ltd
 
Qi-Ye He
Employment - Singlera?Genomics?(Shanghai)?Ltd
 
Zhi-Xi Su
Employment - Singlera?Genomics?(Shanghai)?Ltd
 
Rui Liu
Employment - Singlera?Genomics?(Shanghai)?Ltd
 
Jia Fan
No Relationships to Disclose
 
Jian Zhou
Consulting or Advisory Role - AstraZeneca; MSD
Research Funding - Akeso-Sino Pharma Co., Ltd. (Inst); AstraZeneca (Inst); BeiGene (Inst); Chia Tai Tianqing Pharmaceutical Group (Inst); Eddingpharm (Suzhou) Co., Ltd. (Inst); Eisai China Inc. (Inst); Fosun Pharma (Inst); Gilead Sciences (Inst); Innovent Biologics (Inst); Jiangsu Hengrui Medicine (Inst); Junshi Biosciences (Inst); MSD (Inst); OriCell Therapeutics Co.,Ltd. (Inst); Qilu Pharmaceutical (Inst); Roche (Inst); Singlera genomics (Inst); Suzhou Zelgen Biopharmaceuticals Co., Ltd. (Inst)
 
Xin-Rong Yang
No Relationships to Disclose